Navigation Links
Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
Date:5/14/2008

our vision for Scripps Florida, accelerating the pace of discoveries from the laboratory to the treatment of patients," said Richard A. Lerner, M.D., president of The Scripps Research Institute. "We look forward to continued progress for this program at Poniard."

About The Scripps Research Institute

The Scripps Research Institute is one of the world's largest independent, non-profit biomedical research organizations, at the forefront of basic biomedical science that seeks to comprehend the most fundamental processes of life. Scripps Research is internationally recognized for its discoveries in immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune, cardiovascular, and infectious diseases, and synthetic vaccine development. Established in its current configuration in 1961, it employs approximately 3,000 scientists, postdoctoral fellows, scientific and other technicians, doctoral degree graduate students, and administrative and technical support personnel. Scripps Research is headquartered in La Jolla, California. It also includes Scripps Florida, whose researchers focus on basic biomedical science, drug discovery, and technology development. Currently operating from temporary facilities in Jupiter, Scripps Florida will move to its permanent campus in 2009.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung ca
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... and webcast at 5:00 p.m. Eastern Time (2:00 p.m. ... second quarter 2015 financial results and provide a corporate ... NASDAQ Global Select Market closes that day. ... for domestic callers and 914.495.8552 for international callers. Please ...
(Date:7/30/2015)...  Cardinal Health today reported fourth-quarter fiscal year ... 20 percent, and non-GAAP diluted earnings per share ... of 20 percent. Non-GAAP operating earnings increased 33 ... operating earnings increased 44 percent to $558 million, ... percent to $0.88. Fiscal year 2015 ...
(Date:7/30/2015)... England , July 30, 2015 ... or "The Group") the regenerative medical devices company, ... within the post-acute wound care market as Tissue ... for DermaPure® under Medicare administrator, First Coast Service ... Florida , Puerto Rico ...
Breaking Medicine Technology:Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 2Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 3Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 4Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 2Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 3Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 4Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 5Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 6Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 7Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 8Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 9Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 10Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 11Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 12Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 13Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 14Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 15Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 16Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 17Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 18Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 19Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 20Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 21Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 22Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 23Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 24Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 25Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 26Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 27Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 28Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 29Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 30Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 31Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 32Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 33
... Roper Industries, Inc.   (NYSE: ... 2009, ended December 31, 2009 , will be released before the ... to discuss these results has been scheduled for 8:30 AM ET ... accessed via webcast or by dialing +1 888-539-3679 (US/ Canada ) or ...
... SAN DIEGO , Jan. 20 First Coast ... to treat breast cancer with the addition of a Naviscan PEM ... in the nation to use both a PEM scanner and the ... , AccuBoost is a technique for whole breast irradiation that is ...
Cached Medicine Technology:First Coast Oncology Deploying Both Naviscan(TM) PEM and AccuBoost(TM) Assisted Therapy to Optimize Breast Cancer Treatment 2First Coast Oncology Deploying Both Naviscan(TM) PEM and AccuBoost(TM) Assisted Therapy to Optimize Breast Cancer Treatment 3
(Date:7/30/2015)... ... July 30, 2015 , ... New research finds some ... here to read more on the Surviving Mesothelioma website. , Researchers with ... Missouri reviewed more than 12,000 cases of mesothelioma occurring between 1990 and 2010. Two ...
(Date:7/30/2015)... , ... July 30, 2015 , ... 1Heart Caregiver Services ... - “Learn How to Make Money in the Booming Homecare Business.” This will be ... 90010. , The event will be hosted by 1Heart’s very own ...
(Date:7/30/2015)... ... ... After conducting a nationwide executive search led by healthcare leadership solutions firm ... N.Y., has hired Gerard (Jerry) Walsh as Chief Executive Officer. Walsh assumed his new ... Walsh is an expert in organizational change, physician development, implementation of quality and patient ...
(Date:7/30/2015)... DC (PRWEB) , ... July 30, 2015 , ... ... a fight with its Medicare administrative contractor (MAC) over submitted claims for bariatric ... Calling it a challenge to program integrity, Becky Dennis, a nurse auditor at ...
(Date:7/30/2015)... Hanover, MA (PRWEB) , ... July 30, 2015 ... ... just awarded the largest amount of research grants in its history of funding ... for medical professionals who have dedicated their life’s work toward scientific research directed ...
Breaking Medicine News(10 mins):Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2Health News:Upcoming Business Seminar at 1Heart Caregiver Services Headquarters Los Angeles California 2Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 2Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 3Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 4Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 5Health News:Hospital Details Fight for Bariatric Surgery Reimbursement in AIS Newsletter 2Health News:Hospital Details Fight for Bariatric Surgery Reimbursement in AIS Newsletter 3Health News:Brain Aneurysm Foundation to Award Largest Amount of Research Funding 2Health News:Brain Aneurysm Foundation to Award Largest Amount of Research Funding 3Health News:Brain Aneurysm Foundation to Award Largest Amount of Research Funding 4
... ... Discovery Health, - PREGNANT MAN Premieres Tuesday, November 18, at ... November 19, at 10:00 PM ET/PT -, SILVER SPRING, Md., Nov. ... Thomas Beatie tells the definitive story of,his first pregnancy this Tuesday on ...
... DALLAS, Nov. 13 As Sandy Mullen and ... they were,caring for in the eating disorders unit ... the seemingly successful treatment of a,patient,s primary addiction ... After reviewing hundreds of cases, Mullen, RN, an ...
... 13 Nile Therapeutics,Inc. (Nasdaq: NLTX ), a ... cardiovascular disease, today announced financial results,for the three and ... loss for the three months ended September 30, 2008 ... million, or $0.35 per,share, for the same period of ...
... learned might one day lead to vaccine that works , , ... develop an AIDS vaccine has failed, but researchers report that ... one more effective. , "It,s raised a whole new set ... answer to get us to a successful vaccine," said Dr. ...
... Corp. (Nasdaq:,HMSY) today announced that it will present at ... November 18-19, 2008 at The New,York Palace Hotel., ... at 11:00 am,ET., HMS Holdings Corp. (Nasdaq: ... and program integrity services for government,healthcare programs. The company,s ...
... N.J., Nov. 13 Medco Health,Solutions, Inc. (NYSE: ... Jr., and other members of the Medco senior leadership ... financial results and,business outlook to analysts and investors during ... titled "Inventing World-Class Healthcare,Solutions," is scheduled to begin at ...
Cached Medicine News:Health News:Pregnant Man Thomas Beatie Is Pregnant Again 2Health News:Pregnant Man Thomas Beatie Is Pregnant Again 3Health News:Dallas Addiction Specialists Reveal Discovery in New Book 2Health News:Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results 2Health News:Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results 3Health News:Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results 4Health News:Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results 5Health News:HIV Vaccine Failure Still Brings Insights 2Health News:Medco to Webcast 2008 Analyst Day Conference 2
... cutting speeds (guillotine movements) are possible. Cutting ... off, thus minimizing tissue trauma. One can ... both can be combined together. There are ... bi-manual techniques. Lightweight autoclavable hand-pieces with single ...
A wide selection of bipolar forceps and hemostatic erasers to facilitate most ophthalmic surgical procedures....
Enables Delicate Lifting Of The Flap Without Causing Trauma - Also available in Titanium...
The CGIL iridectomy contact glass was designed by Riquin, Fankhauser et al. to perform full thickness peripheral laser iridectomies....
Medicine Products: